Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atazanavir.

David R Goldsmith1, Caroline M Perry

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|August 9, 2003
PubMed
Summary
This summary is machine-generated.

Atazanavir, an HIV-1 protease inhibitor, effectively reduces viral load with a distinct resistance profile. This treatment shows favorable lipid profiles and allows once-daily dosing, with nausea as a notable side effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Monocyte abundance and glycolytic reprogramming associate with motivational impairment in depression.

Brain, behavior, and immunity·2026
Same author

Managing Recurrent Postictal Worsening of Psychosis in Clozapine-Treated Schizophrenia: A Case Report.

Case reports in psychiatry·2026
Same author

Metabolic monitoring and control among patients with type 2 diabetes prescribed second generation antipsychotics.

Psychiatry research·2025
Same author

A neutrophil-to-lymphocyte ratio higher than 3 may identify infl ammation during clozapine titrations: A re-analysis of five published cases of myocarditis.

Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology·2025
Same author

Weight change from incretin-based weight loss medications across categories of second-generation antipsychotics.

International journal of obesity (2005)·2025
Same author

The moderating role of lifetime social engagement on the relationship between C-reactive protein and negative symptoms among young adults at clinical high risk for psychosis.

Brain, behavior, and immunity·2025
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Infectious Diseases

Background:

  • Atazanavir is a novel azapeptide protease inhibitor targeting HIV-1 protease.
  • It exhibits high specificity and activity against the virus.
  • A distinct resistance profile is associated with atazanavir, characterized by the I50 L protease substitution.

Purpose of the Study:

  • To evaluate the efficacy and safety of atazanavir in HIV-1 treatment.
  • To assess the pharmacokinetic profile and drug interactions of atazanavir.
  • To compare the viral load reduction efficacy of atazanavir with nelfinavir.

Main Methods:

  • Clinical trial evaluating atazanavir in combination with stavudine and didanosine.
  • Assessment of viral load reduction, lipid profiles, and adverse events.

Related Experiment Videos

  • Pharmacokinetic analysis of atazanavir's once-daily oral administration.

    • Main Results:

    • Atazanavir demonstrated rapid and sustained viral load reduction in treatment-naive patients.
    • No significant increases in total cholesterol, LDL-cholesterol, or triglyceride levels were observed.
    • Atazanavir showed comparable or superior efficacy to nelfinavir in reducing viral load.
    • Nausea was the most common clinically relevant adverse event.

    Conclusions:

    • Atazanavir is an effective HIV-1 protease inhibitor with a favorable safety profile regarding lipid levels.
    • Its pharmacokinetic properties support once-daily dosing.
    • Atazanavir offers a distinct resistance profile and is a viable treatment option for HIV-1 infection.